Cargando…

Serological Biomarkers of Extracellular Matrix Turnover and Neutrophil Activity Are Associated with Long-Term Use of Vedolizumab in Patients with Crohn’s Disease

Crohn’s disease (CD) is a relapsing-remitting inflammatory disease of the gastrointestinal (GI) tract characterized by increased extracellular matrix (ECM) remodeling. The introduction of the α4β7-integrin inhibitor vedolizumab (VEDO) has improved disease management, although there is a high rate of...

Descripción completa

Detalles Bibliográficos
Autores principales:	Alexdottir, Marta S., Bourgonje, Arno R., Karsdal, Morten A., Pehrsson, Martin, Loveikyte, Roberta, van Dullemen, Hendrik M., Visschedijk, Marijn C., Festen, Eleonora A. M., Weersma, Rinse K., Faber, Klaas Nico, Dijkstra, Gerard, Mortensen, Joachim H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329899/ https://www.ncbi.nlm.nih.gov/pubmed/35897710 http://dx.doi.org/10.3390/ijms23158137

Ejemplares similares

Serological Biomarkers of Intestinal Collagen Turnover Identify Early Response to Infliximab Therapy in Patients With Crohn’s Disease
por: Alexdottir, Marta S., et al.
Publicado: (2022)

Serological biomarkers of type I, III and IV collagen turnover are associated with the presence and future progression of stricturing and penetrating Crohnʼs disease
por: Bourgonje, Arno R., et al.
Publicado: (2022)

Hepcidin and Iron Status in Patients With Inflammatory Bowel Disease Undergoing Induction Therapy With Vedolizumab or Infliximab
por: Loveikyte, Roberta, et al.
Publicado: (2023)

Proteomic analyses do not reveal subclinical inflammation in fatigued patients with clinically quiescent inflammatory bowel disease
por: Bourgonje, Arno R., et al.
Publicado: (2022)

Mucosal Eosinophil Abundance in Non-Inflamed Colonic Tissue Is Associated with Response to Vedolizumab Induction Therapy in Inflammatory Bowel Disease
por: Gabriëls, Ruben Y., et al.
Publicado: (2022)

Riboflavin Supplementation in Patients with Crohn’s Disease [the RISE-UP study]
por: von Martels, Julius Z H, et al.
Publicado: (2020)

Use of Tumor Necrosis Factor-α Antagonists Is Associated With Attenuated IgG Antibody Response Against SARS-CoV-2 in Vaccinated Patients With Inflammatory Bowel Disease
por: Otten, Antonius T., et al.
Publicado: (2022)

A Combined Set of Four Serum Inflammatory Biomarkers Reliably Predicts Endoscopic Disease Activity in Inflammatory Bowel Disease
por: Bourgonje, Arno R., et al.
Publicado: (2019)

Polygenetic risk scores do not add predictive power to clinical models for response to anti-TNFα therapy in inflammatory bowel disease
por: Karmi, Naomi, et al.
Publicado: (2021)

Long-Term Dietary Patterns Are Reflected in the Plasma Inflammatory Proteome of Patients with Inflammatory Bowel Disease
por: Bourgonje, Arno R., et al.
Publicado: (2022)

Assessing intestinal permeability in Crohn’s disease patients using orally administered (52)Cr-EDTA
por: von Martels, Julius Z. H., et al.
Publicado: (2019)

Increased fecal calprotectin levels in Crohn’s disease correlate with elevated serum Th1- and Th17-associated cytokines
por: Bourgonje, Arno R., et al.
Publicado: (2018)

Environmental factors associated with biological use and surgery in inflammatory bowel disease
por: van der Sloot, Kimberley W J, et al.
Publicado: (2020)

Serological Biomarkers of Tissue Turnover Identify Responders to Anti-TNF Therapy in Crohn's Disease: A Pilot Study
por: van Haaften, Wouter T., et al.
Publicado: (2020)

The Effect of Phenotype and Genotype on the Plasma Proteome in Patients with Inflammatory Bowel Disease
por: Bourgonje, Arno R, et al.
Publicado: (2021)

HIF1α-Dependent Induction of TFRC by a Combination of Intestinal Inflammation and Systemic Iron Deficiency in Inflammatory Bowel Disease
por: Fagundes, Raphael R., et al.
Publicado: (2022)

Crohn’s Disease in Clinical Remission Is Marked by Systemic Oxidative Stress
por: Bourgonje, Arno R., et al.
Publicado: (2019)

Working towards a comprehensive appraisal of vaccine-induced immunity against SARS-CoV-2 in IBD
por: Otten, Antonius T, et al.
Publicado: (2023)

Clinical Value of Multiomics-Based Biomarker Signatures in Inflammatory Bowel Diseases: Challenges and Opportunities
por: Bourgonje, Arno R., et al.
Publicado: (2023)

Safe and Successful Treatment of Acute Cellular Rejection of an Intestine and Abdominal Wall Transplant With Vedolizumab
por: Trentadue, Guido, et al.
Publicado: (2020)

Isotype-specific Antibody Responses to Mycobacterium avium paratuberculosis Antigens Are Associated With the Use of Biologic Therapy in Inflammatory Bowel Disease
por: van der Sloot, Kimberley W J, et al.
Publicado: (2020)

Vedolizumab in the treatment of Crohn’s disease of the pouch
por: Khan, Freeha, et al.
Publicado: (2018)

Anti-inflammatory Gut Microbial Pathways Are Decreased During Crohn’s Disease Exacerbations
por: Klaassen, Marjolein A Y, et al.
Publicado: (2019)

Large-scale genetic analyses in an understudied disease: haemorrhoidal disease
por: Festen, Eleonora A M, et al.
Publicado: (2021)

Misbalance in type III collagen formation/degradation as a novel serological biomarker for penetrating (Montreal B3) Crohn's disease
por: van Haaften, W. T., et al.
Publicado: (2017)

Inulin-grown Faecalibacterium prausnitzii cross-feeds fructose to the human intestinal epithelium
por: Fagundes, Raphael R., et al.
Publicado: (2021)

The safety of vedolizumab for ulcerative colitis and Crohn's disease
por: Colombel, Jean-Frédéric, et al.
Publicado: (2017)

Vedolizumab for induction and maintenance of remission in Crohn's disease
por: Hui, Samuel, et al.
Publicado: (2023)

The Use of Vedolizumab in Patients with Concomitant Cirrhosis and Crohn’s Disease
por: Kapila, Nikhil, et al.
Publicado: (2018)

Treatment of severe acute ulcerative colitis in SARS-CoV-2 infected patients: report of three cases and discussion of treatment options
por: Bourgonje, Arno R., et al.
Publicado: (2021)

Whole exome sequencing analyses reveal gene–microbiota interactions in the context of IBD
por: Hu, Shixian, et al.
Publicado: (2021)

SLC39A8 missense variant is associated with Crohn's disease but does not have a major impact on gut microbiome composition in healthy subjects
por: Collij, Valerie, et al.
Publicado: (2019)

The quest for genetic risk factors for Crohn's disease in the post-GWAS era
por: Fransen, Karin, et al.
Publicado: (2011)

Is there a role for vedolizumab in the treatment of ulcerative colitis and Crohn’s disease?
por: Gilroy, Leah, et al.
Publicado: (2014)

Ustekinumab and Vedolizumab Dual Biologic Therapy in the Treatment of Crohn's Disease
por: Liu, Eddie Y., et al.
Publicado: (2017)

Intractable pyoderma gangrenosum in a Crohn's disease patient on vedolizumab
por: Yeh, Jennifer E., et al.
Publicado: (2017)

Safety and Efficacy of Vedolizumab in Kidney Transplant Recipients With Crohn’s Disease
por: Busutti, Marco, et al.
Publicado: (2023)

Serological Biomarkers of Joint Tissue Turnover Predict Tocilizumab Response at Baseline
por: Bay-Jensen, Anne C., et al.
Publicado: (2014)

Predicting (side) effects for patients with inflammatory bowel disease: The promise of pharmacogenetics
por: Voskuil, Michiel Dirk, et al.
Publicado: (2019)

Serum Free Thiols Are Superior to Fecal Calprotectin in Reflecting Endoscopic Disease Activity in Inflammatory Bowel Disease
por: Bourgonje, Arno R., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_aso004t5jvdfsvvkrs6guil92b